Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects

Pharmacology Research and Perspectives

Volumn 5, Issue 1, 2017, Pages

  van Meer, Leonie ^a   van Dongen, Marloes ^a   Moerland, Matthijs ^a   de Kam, Marieke ^a   Cohen, Adam ^a   Burggraaf, Jacobus ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

Antisense; oligonucleotide; phase 1 study; renal toxicity; SGLT2 inhibitor

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; GLUCOSE; GLUTATHIONE TRANSFERASE ALPHA; HEMOGLOBIN A1C; ISIS 388626; KIDNEY INJURY MOLECULE 1; N ACETYL BETA GLUCOSAMINIDASE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CLINICAL OUTCOME; COMPLEMENT HEMOLYSIS TEST; CONTROLLED STUDY; DIZZINESS; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FIRST IN HUMAN STUDY; GEL ELECTROPHORESIS; GLUCOSE URINE LEVEL; GLUCOSURIA; HEADACHE; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; KIDNEY DISEASE; LABORATORY TEST; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RHINOPHARYNGITIS; URINALYSIS; URINE SAMPLING;

EID: 85026608730     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.292     Document Type: Article

References (28)

1. Bailey CJ, Iqbal N, T'joen C and List J. F. (2012). Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14: 951–959.
2. Bhanot Sea (2009). ISIS 388626, an SGLT2 antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well-tolerated. [Abstract 328-OR].American Diabetes Association website [online]. 2009. Ref Type: Internet Communication
3. Francis J, Zhang J, Farhi A, Carey H, Geller DS (2004). A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant 19: 2893–2895.
4. Henry SP, Bolte H, Auletta C, Kornbrust DJ (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 120: 145–155.
5. Hoffmann D, Fuchs TC, Henzler T, Matheis KA, Herget T, Dekant W, et al. (2010). Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 277: 49–58.
6. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM (2011). Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300: C14–C21.
7. Jahagirdar V, Barnett AH (2014). Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 15: 2429–2441.
8. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, et al. (2006). Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114: 1729–1735.
9. Kwoh TJ, Crooke ST (2007). Antisense drug technology: principles, strategies, and applications. Pp 365–399. An overview of clinical safety experience of first- and second-generation antisense oligonucleotides. CRC Press, Boca Raton, FL, USA.
10. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130: 461–470.
11. List JF, Woo V, Morales E, Tang W, Fiedorek FT (2009). Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32: 650–657.
12. Liu JJ, Lee T, DeFronzo RA (2012). Why Do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? Diabetes 61: 2199–2204.
13. Monteith DK, Levin AA (1999). Synthetic oligonucleotides: the development of antisense therapeutics. Toxicol Pathol 27: 8–13.
14. Oberbauer R, Schreiner GF, Meyer TW (1995). Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int 48: 1226–1232.
15. Plosker GL (2012). Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 72: 2289–2312.
16. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J (2005). Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427–3434.
17. Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM, et al. (1995). Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney Int 47: 1462–1469.
18. Riser TS, Harris KB (2013). The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 33: 984–999.
19. Sarmiento UM, Perez JR, Becker JM, Narayanan R (1994). In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res Dev 4: 99–107.
20. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, et al. (2002). Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 303: 1334–1343.
21. Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, et al. (2014). Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS ONE 9: e110069.
22. Shah NK, Deeb WE, Choksi R, Epstein BJ (2012). Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 32: 80–94.
23. Srinivasan SK, Iversen P (1995). Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal 9: 129–137.
24. Van ML, Moerland M, Cohen AF, and Burggraaf J (2014). Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development. Br J Clin Pharmacol 77: 947–957.
25. Wancewicz E. (2008.) Long term safety and efficacy of ISIS 388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species. [Abstract 334-OR].American Diabetes Association website [online].
26. Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS (2007). Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35: 460–468.
27. Zanardi TA, Han SC, Jeong EJ, Rime S, Yu RZ, Chakravarty K, et al. (2012). Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second generation antisense oligonucleotide that targets the human sodium glucose cotransporter 2 (SGLT2). J Pharmacol Exp Ther 343: 489–496.
28. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128.